Slack FJ - Search Results

1

ADAR1 and its implications in cancer development and treatment.

Baker AR, Slack FJ. Baker AR, et al. Among authors: slack fj. Trends Genet. 2022 Aug;38(8):821-830. doi: 10.1016/j.tig.2022.03.013. Epub 2022 Apr 19. Trends Genet. 2022. PMID: 35459560 Free PMC article. Review.

2

ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity.

Ramírez-Moya J, Baker AR, Slack FJ, Santisteban P. Ramírez-Moya J, et al. Among authors: slack fj. Oncogene. 2020 Apr;39(18):3738-3753. doi: 10.1038/s41388-020-1248-x. Epub 2020 Mar 10. Oncogene. 2020. PMID: 32157211 Free PMC article.

3

An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks.

Ramírez-Moya J, Miliotis C, Baker AR, Gregory RI, Slack FJ, Santisteban P. Ramírez-Moya J, et al. Among authors: slack fj. Mol Cancer. 2021 Sep 8;20(1):115. doi: 10.1186/s12943-021-01401-y. Mol Cancer. 2021. PMID: 34496885 Free PMC article.

4

Transcriptome Profiling of ADAR1 Targets in Triple-Negative Breast Cancer Cells Reveals Mechanisms for Regulating Growth and Invasion.

Baker AR, Miliotis C, Ramírez-Moya J, Marc T, Vlachos IS, Santisteban P, Slack FJ. Baker AR, et al. Among authors: slack fj. Mol Cancer Res. 2022 Jun 3;20(6):960-971. doi: 10.1158/1541-7786.MCR-21-0604. Mol Cancer Res. 2022. PMID: 35247916 Free PMC article.

5

Junk DNA and the long non-coding RNA twist in cancer genetics.

Ling H, Vincent K, Pichler M, Fodde R, Berindan-Neagoe I, Slack FJ, Calin GA. Ling H, et al. Among authors: slack fj. Oncogene. 2015 Sep 24;34(39):5003-11. doi: 10.1038/onc.2014.456. Epub 2015 Jan 26. Oncogene. 2015. PMID: 25619839 Free PMC article. Review.

6

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.

Rupaimoole R, Slack FJ. Rupaimoole R, et al. Among authors: slack fj. Nat Rev Drug Discov. 2017 Mar;16(3):203-222. doi: 10.1038/nrd.2016.246. Epub 2017 Feb 17. Nat Rev Drug Discov. 2017. PMID: 28209991 Review.

7

Let-7 microRNA as a potential therapeutic target with implications for immunotherapy.

Gilles ME, Slack FJ. Gilles ME, et al. Among authors: slack fj. Expert Opin Ther Targets. 2018 Nov;22(11):929-939. doi: 10.1080/14728222.2018.1535594. Epub 2018 Oct 17. Expert Opin Ther Targets. 2018. PMID: 30328720 Free PMC article. Review.

8

Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing factor.

Jiao AL, Perales R, Umbreit NT, Haswell JR, Piper ME, Adams BD, Pellman D, Kennedy S, Slack FJ. Jiao AL, et al. Among authors: slack fj. RNA. 2019 Mar;25(3):352-363. doi: 10.1261/rna.069773.118. Epub 2018 Dec 11. RNA. 2019. PMID: 30538148 Free PMC article.

9

The Role of Non-coding RNAs in Oncology.

Slack FJ, Chinnaiyan AM. Slack FJ, et al. Cell. 2019 Nov 14;179(5):1033-1055. doi: 10.1016/j.cell.2019.10.017. Cell. 2019. PMID: 31730848 Free PMC article. Review.

10

Challenges identifying efficacious miRNA therapeutics for cancer.

Segal M, Slack FJ. Segal M, et al. Among authors: slack fj. Expert Opin Drug Discov. 2020 Sep;15(9):987-992. doi: 10.1080/17460441.2020.1765770. Epub 2020 May 18. Expert Opin Drug Discov. 2020. PMID: 32421364 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

236 results

Search Page